Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Advanced or Metastatic Non-Small-Cell Lung Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT06188702
What this trial is testing

S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP

Who this might be right for
MTAP-deleted Solid Tumors
Servier Bio-Innovation LLC 60
Testing effectiveness (Phase 2)Active Not RecruitingNCT07703228
What this trial is testing

Second-Line Sacituzumab Tirumotecan Plus Anlotinib for Advanced Driver Gene-Negative Non-Squamous NSCLC

Who this might be right for
NSCLC (Advanced Non-small Cell Lung Cancer)NSCLC Stage IIIB~IVSecond-line Therapy+1 more
Nanfang Hospital, Southern Medical University 38
Early research (Phase 1)Study completedNCT04423029
What this trial is testing

DF6002 Alone and in Combination With Nivolumab

Who this might be right for
Solid Tumors
Dragonfly Therapeutics 170
Not applicableStudy completedNCT03645330
What this trial is testing

Atezolizumab in Patients With Unresectable, Locally Advanced or Metastatic NSCLC (J-TAIL)

Who this might be right for
Non-small-Cell Lung Cancer
Chugai Pharmaceutical 1,026
Large-scale testing (Phase 3)Study completedNCT00017407
What this trial is testing

Carboplatin and Paclitaxel With or Without ISIS 3521 in Treating Patients With Non-Small Cell Lung Cancer

Who this might be right for
Lung Cancer
Ionis Pharmaceuticals, Inc.
Testing effectiveness (Phase 2)Study completedNCT02797964
What this trial is testing

A Phase 1/2 Trial of SRA737 in Subjects With Advanced Cancer

Who this might be right for
Advanced Solid Tumors or Non-Hodgkin's Lymphoma (NHL)
Sierra Oncology LLC - a GSK company 107
Not applicableLooking for participantsNCT07696832
What this trial is testing

Efficacy and Safety of Ivonescimab Monotherapy as First-Line Treatment for PD-L1-Positive, Driver Gene-Negative, Locally Advanced or Metastatic NSCLC: A Multicenter, Prospective, Real-World Cohort Study

Who this might be right for
Patients Must Have Histologically or Cytologically Confirmed Locally Advanced or Metastatic NSCLCEGFR Mutation-negative and ALK Rearrangement-negativeEastern Cooperative Oncology Group Performance Status (ECOG PS) Score of 0 to 2+2 more
Guangdong Association of Clinical Trials
Post-approval studies (Phase 4)Study completedNCT03285763
What this trial is testing

Atezolizumab (Tecentriq) to Investigate Long-term Safety and Efficacy in Previously-treated Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Hoffmann-La Roche 619
Testing effectiveness (Phase 2)UnknownNCT04872634
What this trial is testing

Evaluate the Safety and Anti-tumor Activity of SNK01 (NK Cells) Administered in Combination With Chemotherapy or Chemotherapy / Cetuximab in Local Advanced or Metastatic Non-small Cell Lung Cancer Patients Who Failed Tyrosine Kinase Inhibitor Treatment

Who this might be right for
Non-small Cell Lung Cancer
NKMAX Co., Ltd. 24
Large-scale testing (Phase 3)Looking for participantsNCT06956001
What this trial is testing

Firmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for NSCLC With EGFR PACC or EGFR l861q Mutation

Who this might be right for
EGFRNSCLC (Advanced Non-small Cell Lung Cancer)
Allist Pharmaceuticals, Inc. 300
Testing effectiveness (Phase 2)Active Not RecruitingNCT05445843
What this trial is testing

Study of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C- Mutated Non-small Cell Lung Cancer With a PD-L1 Expression < 1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation.

Who this might be right for
Locally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation
Novartis Pharmaceuticals 95
Testing effectiveness (Phase 2)Ended earlyNCT02580708
What this trial is testing

Phase 1/2 Study of the Safety and Efficacy of Rociletinib in Combination With Trametinib in Patients With mEGFR-positive Advanced or Metastatic Non-small Cell Lung Cancer

Who this might be right for
Non-small Cell Lung Cancer
Clovis Oncology, Inc. 7
Testing effectiveness (Phase 2)Study completedNCT00986674
What this trial is testing

Carboplatin and Paclitaxel Combined With Cetuximab and/or IMC-A12 in Patients With Advanced Non-Small Cell Lung Cancer

Who this might be right for
Recurrent Non-small Cell Lung CancerStage IIIB Non-small Cell Lung CancerStage IV Non-small Cell Lung Cancer
National Cancer Institute (NCI) 140
Testing effectiveness (Phase 2)Active Not RecruitingNCT02955290
What this trial is testing

CIMAvax Vaccine, Nivolumab, and Pembrolizumab in Treating Patients With Advanced Non-small Cell Lung Cancer or Squamous Head and Neck Cancer

Who this might be right for
Advanced Head and Neck Squamous Cell CarcinomaLung Non-Small Cell CarcinomaMetastatic Lung Non-Small Cell Carcinoma+13 more
Roswell Park Cancer Institute 51
Testing effectiveness (Phase 2)Active Not RecruitingNCT04225117
What this trial is testing

Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)

Who this might be right for
Locally Advanced or Metastatic Malignant Solid Tumors
Astellas Pharma Global Development, Inc. 329
Large-scale testing (Phase 3)Study completedNCT00556712
What this trial is testing

Tarceva (Erlotinib) Following Platinum-Based Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Who this might be right for
Non-Small Cell Lung Cancer
Hoffmann-La Roche 889
Testing effectiveness (Phase 2)Study completedNCT00003989
What this trial is testing

ISIS 3521 in Treating Patients With Advanced, Unresectable, or Metastatic Non-small Cell Lung Cancer or Unresectable or Metastatic Melanoma

Who this might be right for
Lung CancerMelanoma (Skin)
European Organisation for Research and Treatment of Cancer - EORTC 50
Early research (Phase 1)Ended earlyNCT04892017
What this trial is testing

Study of Inlexisertib (DCC-3116) in Participants With RAS/MAPK Pathway Mutant Solid Tumors

Who this might be right for
Non-Small Cell Lung CancerAdvanced Solid TumorMetastatic Solid Tumor
Deciphera Pharmaceuticals, LLC 91
Testing effectiveness (Phase 2)Study completedNCT00118183
What this trial is testing

Docetaxel With Either Cetuximab or Bortezomib as First-Line Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

Who this might be right for
Adenocarcinoma of the LungAdenosquamous Cell Lung CancerLarge Cell Lung Cancer+5 more
National Cancer Institute (NCI) 62
Testing effectiveness (Phase 2)Study completedNCT00547105
What this trial is testing

Erlotinib and SBRT in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Who this might be right for
Lung Cancer
University of Texas Southwestern Medical Center 24
Next Page
265